The Citizens Commission on Human Rights (CCHR) today urged consumers to examine psychotropic prescription drug labeling for warnings about suicide, aggression, and homicidal ideation, and to demand that prescribing physicians explain these risks, even when they are listed as rare. The call follows media reports of violent crimes allegedly linked to prescribed psychiatric medications, underscoring a broader concern about patient awareness and informed consent.
CCHR's decades-long advocacy has highlighted documented side effects such as agitation, aggression, suicidal behavior, and homicidal thoughts associated with some psychotropic drugs. Regulatory bodies in the U.S. and abroad have responded by requiring warnings in drug labeling. Jan Eastgate, president of CCHR International, emphasized that a rare warning buried in a package insert does not substitute for a doctor explaining the risk to a patient. Listing a side effect as 'rare' does not establish that the patient was told about it, understood it, or agreed to take that risk. Meaningful informed consent requires meaningful disclosure and prescriber accountability.
The issue is gaining attention in legal and psychiatric circles. Psychiatric Times recently published an article titled "Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients' Criminal Behavior?" discussing a high-profile murder case where the defense argued that psychiatric polypharmacy contributed to violent behavior. The journal noted that "a good portion of the public and the media appear to support the defense theory" and that the litigation "places psychiatrists and other mental health providers under scrutiny." The authors concluded that "psychiatry itself may end up on trial."
When prescribed drugs are alleged to induce violent or criminal behavior, one legal doctrine is involuntary intoxication. Its applicability depends on the facts and governing law, including whether the drug was taken as prescribed and whether the person knew of the particular intoxicating effect. Eastgate added that a judge allowing a jury to hear evidence about prescription drugs is not the same as a physician warning a patient before the first dose. The existence of a warning in drug labeling does not, by itself, establish that an individual patient was adequately informed.
This concern is not new. In a December 2005 Psychiatric Times article on psychopharmacology liability, the journal discussed psychiatrists' duties in light of the FDA's 2004 public health advisory on antidepressants, which identified reports of anxiety, agitation, hostility, aggression, and other behavioral effects. The FDA later required a boxed warning on suicidality for children and adolescents, later expanded to young adults.
CCHR's compilation of international regulatory warnings identifies 57 warnings or safety notices since 2004 involving violence, aggression, or hostility—a 1,040% increase from five in 2004. Thirteen of those notices specifically reference homicidal ideation. Examples include the addition of homicidal ideation to labeling for extended-release venlafaxine in 2005, a boxed neuropsychiatric warning for bupropion in 2009, and a 2023 FDA class-wide warning for stimulants about anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation. Esketamine nasal spray labeling instructs patients to seek medical attention for mood changes, including acting aggressively or violently, and aripiprazole lists homicidal ideation as a rare adverse reaction.
For CCHR, the core issue is that printing a warning does not ensure a patient has seen it, understood it, or discussed it with a physician. This concern has entered public policy: a 2026 Tennessee law requires toxicology testing for psychiatric and other drugs after specified violent incidents, and CCHR advocates for similar laws in every state.
Eastgate stated, "Drug labeling now contains warnings and adverse-event information that consumers have a right to know about. While not all individuals taking a prescription psychotropic drug will become violent or suicidal, they should read these warnings and ask questions before agreeing to treatment. Prescribers should explain potentially serious violent and suicidal adverse effects—including those considered rare—and document that the patient was given the information necessary to make an informed decision. A label alone does not ensure informed consent."
Ultimately, the issue is not whether every patient will experience these reactions, but whether patients are adequately informed when regulators and manufacturers have identified potentially serious behavioral adverse effects—and whether prescribers are held accountable for ensuring that patients are warned. Patients should not abruptly stop taking psychiatric drugs; any reduction or discontinuation should be medically supervised.
CCHR, established in 1969 by the Church of Scientology and Dr. Thomas Szasz, maintains that transparent disclosure of known risks and prescriber accountability are fundamental to meaningful informed consent.
